1460-1461 / 2437
Infant Medulloblastoma
- Management problematic
- Most protocols involve avoidance (or 1-2 yrs post-
poning) of routine CSRT
- Most protocols have accepted impaired outcome and
need for RT as salvage, when treatment is more
difficult
- Lack of data on long-term quality of life outcome
So far it has been feasible to deliver reduced dose CSRT for high risk MB in
infants, but toxicity of full dose (35-36 Gy) CSRT is problematic